Skip to content

PHARMAX

Active Public limited companyfounded 1997active for 29 yearsRue de Visé 26, 4020 LiègeKBO/BCE: BE 0461.189.963

Lifetime

20 annual accounts with figures on one time axis, 28 filings since 1998
peak of €124,126 in 2010
€108,249▼ 2.7%
peak of €78,738 in 2024
€76,733▼ 2.5%
peak of €459,428 in 2024
€457,161▼ 0.5%
€129,116▲ 11.8%
peak of 1.2 FTE in 2006
-not published
Board5 names since 1997
3 directors and 2 others
Documentsfilings and deeds
24-06-202637 days before the deadline
2025micro format
Dividend €79,000

Key points

from the 2025 annual accounts

Equity

€457,161 ▼ 0.5%
459,4282024+76,733Profit-79,000Dividend457,1612025

PHARMAX paid out €79,000 in dividends. That is 103% of the 2025 profit.

Filings

28 annual accounts since 1998
AprilJune31 JulyOctober200020102020

The last five annual accounts were filed 14 to 38 days before the end of the period.

Position in the sector

€457,161

More equity than 95% of companies in retail trade. The sector median is €40,794, over 25,465 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as PHARMAX has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for PHARMAX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 14-07-1997
Director, since 19-12-2023
Director, since 19-12-2023
Board & ownership

Recent changes

2 directors appointed, 1 resignation, 1 reappointment reappointed · resigns · and appointed · General meeting of 19-12-2023 · Gazette deed
1 director appointed, 1 resignation, 1 reappointment resigns as managing director · appointed as managing director · reappointed as managing director · Gazette deed
First establishment Rue de Visé 26, Liège
Incorporation published on 02-08-1997 · Gazette deed
All 33 events

Comparable companies

same main activity, similar in size and age
Company
PHARMAX Liège €586,278 €108,249 78.0% -
APOTHEEK MOEREMANS Ninove €590,537 €102,118 54.5% -
ST FARMA Ghent €539,584 €104,932 63.8% 0.4
APOTHEEK HEYVAERTS Antwerp €529,676 €108,203 43.3% -
APOTHEEK HENDRICKX Kalmthout €575,928 €125,587 62.9% 1
APOTHEEK VERMASSEN Nazareth-De Pinte €539,917 €118,424 82.8% 0
Pharmacie de Stoumont Stoumont €574,980 €131,747 9.2% 0

These companies have the same main activity as PHARMAX: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €530,000 and €591,000, founded between 1995 and 1999.

Official details

Source: KBO
Status
Active since 23-07-1997Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.085.453.8744020 Liège, since 11-02-1998
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

≈ €380,000estimated
€586,278▲ 2.0%
Filing
Filed on 24-06-2026, 37 days before the end of the filing period
Financials

Insights on PHARMAX

PHARMAX files the micro format. That format states no turnover. The gross margin rose from €78,486 in 2006 to €108,249 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMAX

What is the company number of PHARMAX?
The company number of PHARMAX is 0461.189.963. The VAT number is the same number with BE in front: BE 0461.189.963.
Where is PHARMAX based?
The registered office is at Rue de Visé 26, 4020 Liège.Company details
What does PHARMAX do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMAX?
PHARMAX is a public limited company (NV).
When was PHARMAX founded?
PHARMAX was founded on 23-07-1997.
Is PHARMAX still active?
Yes, PHARMAX is an active enterprise in the KBO register.
How many employees does PHARMAX have?
PHARMAX had an average of 0.8 full-time equivalents in financial year 2018, according to the filed annual accounts.Financials
What is the turnover of PHARMAX?
The turnover in financial year 2025 is about €380,000. This figure is estimated from the gross margin of €108,249 and 37 comparable companies (NACE 477). It probably lies between €280,000 and €640,000. In financial year 2019 turnover was €771,322.
Is PHARMAX profitable?
In financial year 2025, PHARMAX made a profit of €76,733.
Where can I find the annual accounts of PHARMAX?
PHARMAX filed 28 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMAX due?
PHARMAX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.